Female Pattern Hair Loss: How It Differs from Male AGA
Published by AmpleLab Research
Female pattern hair loss is the most common hair disorder in women, yet it receives substantially less attention in both clinical literature and the hair loss community than its male equivalent. The online spaces where hair loss is researched (forums, social media, YouTube) are largely male-dominated, and the discussions, product recommendations, and protocol frameworks that circulate there are built primarily around androgenetic alopecia in men. Women navigating the same search terms often encounter advice calibrated for a different condition.
FPHL shares some features with male AGA but differs in important ways: the pattern, the hormonal picture, the role of androgens, and the treatment options are all distinct enough that applying male AGA frameworks directly to women produces unreliable results. This article covers what FPHL is, how and why it differs from the male pattern, what the diagnosis involves, and where the available interventions sit.
Female pattern hair loss (FPHL) is a non-scarring, progressive condition characterised by a reduction in hair density over the crown and frontal scalp, with diffuse miniaturisation of terminal follicles. The frontal hairline is typically preserved, distinguishing it immediately from the most common male presentations of AGA. The condition can begin as early as the teenage years but becomes substantially more prevalent after menopause, with estimates suggesting it affects roughly 6% of women under 50 and approximately 38% of women over 70.
The condition was historically called female androgenetic alopecia (FAGA), directly mirroring the male diagnosis. The terminology has largely shifted to FPHL in recent years, and that shift reflects something substantive: a meaningful proportion of women with the condition have entirely normal androgen levels. Calling it androgenetic implies an androgen cause that is, in many cases, absent or minimal. FPHL is the preferred term precisely because it describes the pattern without presupposing the mechanism.
Severity is typically graded on the Ludwig scale, which describes three stages: Ludwig I is a perceptible widening of the central part with maintained density; Ludwig II is more pronounced thinning across the crown; Ludwig III is near-complete loss over the top of the scalp with relative frontal hairline preservation throughout. A "Christmas tree" distribution, where thinning is widest at the front and narrows toward the crown, is a clinically recognised variant.
In men, AGA is driven primarily and consistently by DHT acting on androgen-sensitive follicles. The pathway is well-established: testosterone is converted to DHT by 5-alpha reductase in dermal papilla cells; DHT binds androgen receptors and progressively shortens the anagen phase; follicles miniaturise over successive cycles. The article on DHT and the follicle covers this mechanism in detail.
In women, the picture is genuinely more complex, and four features distinguish it from the male model:
Most women with FPHL do not demonstrate clinically significant androgen excess on routine hormonal testing. Serum testosterone, free androgen index, and DHEAS are normal in the majority of cases. The condition proceeds in many women through mechanisms that are not well-characterised and may involve follicle ageing, genetic susceptibility independent of androgen sensitivity, and hormonal factors beyond the classic DHT pathway. This is not universal: some women with FPHL do have androgen excess, particularly those also presenting with signs of hyperandrogenism such as hirsutism, acne, irregular menses, or features of polycystic ovary syndrome (PCOS). In those cases the mechanism is closer to the male model. But they are the minority.
Oestrogen receptors are present in hair follicles, and oestrogen is understood to have a generally protective effect on hair cycling, associated with prolonged anagen. The marked increase in FPHL prevalence around and after menopause is consistent with a protective effect being lost as oestrogen levels decline, rather than simply reflecting accumulated years of androgen exposure. This is a mechanism with no equivalent in male AGA, and it explains why post-menopausal women may experience onset or worsening of FPHL even with no change in androgen levels.
Women's scalp tissue contains higher aromatase activity than men's. Aromatase converts androgens to oestrogens locally, providing a degree of intrafollicular protection from DHT in women's scalp follicles. This is likely one reason why FPHL, even when androgen-mediated, tends to be less severe and less complete than male AGA. The occipital follicles and the frontal hairline retain greater resistance, and total follicle loss of the kind seen in advanced male AGA is rare in women.
Women's scalp follicles express lower levels of androgen receptors overall compared to men's, and the distribution differs across scalp regions. This lower receptor density likely accounts for both the less severe overall presentation and the characteristic preservation of the frontal hairline: in women, even the follicles of the frontal scalp appear relatively resistant to androgen signalling compared with the vertex and crown, whereas in men the temporal and frontal follicles are among the most susceptible.
A clinical diagnosis of FPHL in women is made on the pattern of hair loss, typically supported by trichoscopy showing miniaturised hairs, perifollicular changes, and an increased proportion of single-hair follicular units in affected areas. This much is similar to male AGA. What differs is the necessary investigative workup.
Because many women presenting with diffuse crown thinning have telogen effluvium rather than or in addition to FPHL, and because TE can be triggered by iron deficiency and thyroid dysfunction that are significantly more common in women, blood work is not optional in the diagnostic process. At minimum, ferritin and thyroid function (TSH, free T4) should be assessed. Ferritin is particularly important: the laboratory reference range for "normal" is calibrated for anaemia prevention, not optimal hair cycling, and many hair loss specialists use a considerably higher threshold for hair health than standard lab reference ranges imply. An apparently normal ferritin result may still be clinically meaningful in the context of hair loss.
Where signs of hyperandrogenism are present (hirsutism, acne, irregular periods, weight changes) a hormonal panel is required: serum testosterone, free androgen index, DHEAS, prolactin, and where relevant, investigations for PCOS or adrenal abnormalities. The presence of elevated androgens changes both the diagnosis and the treatment approach substantially. For a full account of how to distinguish FPHL from telogen effluvium, the article on telogen effluvium vs androgenetic alopecia is a useful companion piece.
The treatment evidence base for FPHL is thinner than for male AGA. The flagship male treatments, finasteride and dutasteride, have a more complicated position in women, and most anti-androgen options are used off-label. What is available:
Topical minoxidil 2% is licensed in the UK for women with FPHL. It is the most well-evidenced topical option available, with randomised controlled trial data showing stabilisation and partial density improvement in a meaningful proportion of users. It works via potassium channel opening and VEGF upregulation, mechanisms that are not sex-specific and are independent of the androgen pathway, which partly explains why it can be effective in women regardless of their androgen status. Minoxidil 5% formulations are also used in women in clinical practice, though the 2% licence specifically covers women.
Oral minoxidil at low doses (typically 0.25–1mg in women) is used off-label in clinical hair loss practice, with a growing evidence base and a more manageable side effect profile at these doses than at the higher doses historically used for blood pressure. It offers systemic delivery and may be preferred for women who find topical application difficult. It is not licensed for hair loss in this oral form.
An aldosterone antagonist with anti-androgenic properties, spironolactone is used off-label for FPHL in women with androgen-sensitive pattern loss or with signs of hyperandrogenism. Evidence includes case series and small trials. Doses used in hair loss practice (typically 50–200mg daily) require monitoring for effects on blood pressure and electrolytes. Contraindicated in pregnancy.
5-AR inhibitors have a more limited role in women than in men. Finasteride is not licensed for hair loss in women in the UK and is absolutely contraindicated in women who are pregnant or could become pregnant due to the risk of feminisation of a male foetus. The evidence for finasteride in post-menopausal women or women with confirmed androgen excess is more supportive but remains off-label. Dutasteride has even less data in women. Where these are used, it is under specialist dermatology supervision with appropriate contraception in women of childbearing potential.
For premenopausal women with androgen-driven FPHL or hyperandrogenism, a combined OCP containing a progestogen with anti-androgenic properties (such as cyproterone acetate or drospirenone) can reduce androgen-mediated follicle signalling. This is a treatment option specific to women of reproductive age with no equivalent in male AGA.
The downstream follicular consequences of FPHL (reduced perifollicular vascularisation, changes to the extracellular matrix environment, and shortened anagen phases) are broadly similar to those in male AGA. This means that topical actives studied in the context of follicle biology are potentially relevant for women with FPHL regardless of whether their condition is androgen-driven.
Copper peptides act on the follicular microenvironment rather than on the androgen pathway. GHK-Cu has a research profile centred on tissue remodelling, extracellular matrix support, and growth factor modulation. AHK-Cu has been investigated in vitro for effects on dermal papilla cells and hair follicle elongation. Neither compound acts on androgens or oestrogen; they are not androgen-dependent in their mechanism. The 1% AHK-Cu Hair and Scalp Serum and the 1% GHK-Cu Face and Skin Serum are positioned as adjuncts to the follicular environment, consistent with that mechanism. For women building a protocol, the hair loss protocol guide covers how different approaches sit relative to each other.
Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review
Starace M et al. — International Journal of Women's Dermatology, 2019 PubMed ↗
The female pattern hair loss: review of etiopathogenesis and diagnosis
Ramos PM, Miot HA — Anais Brasileiros de Dermatologia, 2015 PubMed ↗
Female pattern hair loss
Vujovic S, Ivovic M — Vojnosanitetski Pregled, 2015 PubMed ↗
Why does my frontal hairline look fine but my parting has widened?
This is the classic early presentation of FPHL. The frontal hairline follicles in women are relatively resistant to the processes driving crown thinning, whether androgen-mediated or not. Widening of the central parting is often the first visible sign of FPHL: it reflects reduced density in the crown region before the hairline is involved. If the thinning is diffuse across the entire scalp including the sides and back rather than concentrated over the crown and parting, telogen effluvium is a more likely explanation and should be investigated separately.
My blood tests show normal testosterone: can I still have FPHL?
Yes. Most women with FPHL have normal androgen levels. The condition is not dependent on elevated androgens in the way male AGA is. Normal testosterone does not rule out FPHL; it rules out androgen excess as the primary driver, which affects which treatments are most appropriate but does not change the diagnosis if the clinical pattern is consistent with FPHL. Trichoscopy showing miniaturisation in the crown with preserved frontal density supports the diagnosis independently of androgen status.
Can I use the same treatments as men with AGA?
Minoxidil is shared: it is licensed for both men and women and works via an androgen-independent mechanism. 5-AR inhibitors (finasteride, dutasteride) are substantially more restricted in women: they are not licensed for hair loss in women in the UK, carry teratogenicity concerns in women of childbearing potential, and the evidence base in women is narrower. Women have additional options not used in men: spironolactone, anti-androgenic oral contraceptives, and oestrogen-based approaches in appropriate post-menopausal candidates. Treatment for FPHL should be tailored by a dermatologist who can account for androgen status, childbearing considerations, and the specific clinical pattern.
Does FPHL worsen after menopause?
For many women, yes. The increase in FPHL prevalence with age, and particularly the marked increase in and after the perimenopausal period, is consistent with falling oestrogen levels removing a protective effect on hair cycling. Women who notice accelerating thinning around menopause should seek assessment, as this is a clinically recognised pattern and the timing is meaningful for diagnosis. Whether hormone replacement therapy (HRT) has a meaningful impact on FPHL is a question for a menopause specialist and endocrinologist, as the evidence is mixed and HRT decisions involve multiple considerations beyond hair.
Are copper peptide serums relevant for women with FPHL?
The mechanisms copper peptides are studied for (tissue remodelling, extracellular matrix support, vascular growth factor modulation) are not androgen-dependent. The downstream follicular microenvironment changes associated with FPHL (reduced perifollicular vascularisation, changes in matrix composition around the follicle) are broadly similar to those in male AGA. As adjuncts to a protocol that addresses the primary cause, copper peptides are as relevant for women with FPHL as for men with AGA. They are not treatments for FPHL and do not address the hormonal or genetic mechanisms driving it.
This article is provided for educational purposes and does not constitute medical advice. FPHL diagnosis and treatment require assessment by a qualified healthcare professional. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.